Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.36 |
| ▸ | CPS1 | P31327 | 1/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475543 | 1.00 | ERN1 (0.40) | ERN1PROKR1ALDH1A1LMNAHPGD | |
| SCHEMBL30476673 | 0.85 | ERN1 (0.42) | ERN1ALDH1A1LMNAHPGD | |
| SCHEMBL29475596 | 0.85 | ERN1 (0.42) | ERN1ALDH1A1LMNAHPGD | |
| SCHEMBL25322131 | 0.85 | ERN1 (0.42) | ERN1ALDH1A1LMNAHPGD | |
| SCHEMBL25318324 | 0.85 | ERN1 (0.42) | ERN1ALDH1A1LMNAHPGD | |
| SCHEMBL29475564 | 0.85 | ERN1 (0.42) | ERN1ALDH1A1LMNAHPGD | |
| SCHEMBL25320430 | 0.85 | ERN1 (0.42) | ERN1ALDH1A1LMNAHPGD | |
| SCHEMBL17040279 | 0.70 | MAOA (0.44) | LMNAHPGD | |
| SCHEMBL25317544 | 0.69 | ERN1 (0.47) | ERN1PROKR1ALDH1A1LMNAHPGD | |
| SCHEMBL29475606 | 0.69 | ERN1 (0.47) | ERN1PROKR1ALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4217342-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | Neuropore Therapies, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116507607-A | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | ERN1 738/4885PROKR1 4708/4885ALDH1A1 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.